ENTITY
CANbridge Pharmaceuticals

CANbridge Pharmaceuticals (1228 HK)

8
Analysis
Health Care • China
CANbridge Pharmaceuticals is a global biopharmaceutical company dedicated to the research, development, and commercialization of transformative therapies for rare diseases and oncology. The company offers approved drugs such as Hunterase for Hunter syndrome and Livmarli for Alagille syndrome, and is developing a pipeline of gene therapies and other assets. It was founded in 2012 and is headquartered in Suzhou, China.
more
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
x